Medical Science News

RSS

NEDD9 protein plays significant role in development of HER2-driven breast cancer: Researchers

Researchers at Fox Chase Cancer Center have identified a potentially significant molecular player in the development of aggressive breast cancer. The team's findings show that a protein called NEDD9 is critical in the formation of breast tumors induced by high levels of the cell-surface receptor HER2/neu in mice.

21 Apr 2010

Semafore Pharmaceuticals' SF1126 PI3K-mTOR inhibitor demonstrates broad anti-tumor activity in lymphoma

Semafore Pharmaceuticals today announced the presentation of data demonstrating that SF1126, a novel small molecule inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), has broad preclinical anti-tumor activity in multiple myeloma and lymphoma. Data were presented in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting in Washington, D.C.

21 Apr 2010

New web-based service for analyzing, visualizing and managing DNA sequencing data

DNAnexus, Inc. today announced the commercial launch of its web-based service for analyzing, visualizing, and managing next-generation DNA sequencing data. Andreas Sundquist, Ph.D., co-founder and CEO, will introduce the solution publicly for the first time today at the annual Bio-IT World Conference and Expo in Boston, Massachusetts.

20 Apr 2010

Platelet rich plasma helps speed healing and bone formation following tooth removal

The use of platelet rich plasma (PRP) following tooth removal appears to speed healing and bone formation, according to an article in the Journal of Oral Implantology.

20 Apr 2010

MUC1 expression indicates progression of pediatric inflammatory bowel disease

Millions of people are afflicted with inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, and 30 percent of new cases occur in childhood. Mucin 1, an epithelial mucin that has been shown to elicit both an immune response and to have altered glycosylation in disease, may be a noninvasive indicator of the progression of these illnesses.

20 Apr 2010

Affymetrix introduces new service for obtaining allele-specific copy number data from FFPE samples

Affymetrix, Inc. today announced the launch of the Affymetrix® MIP Copy Number Service, designed for cancer researchers using challenging FFPE samples. With the MIP Copy Number Service, scientists can now obtain high-quality allele-specific copy number data from FFPE samples. The service is available for research use only exclusively through the Affymetrix® Research Services Laboratory (ARSL).

20 Apr 2010

Genetic defect in protein glycogenin can lead to cardiac arrest

Researchers have discovered a new disorder linked to heart problems that stems from a genetic defect in the protein glycogenin. In a worst case scenario, disruption of this protein's function can lead to cardiac arrest, which is exactly what happened to the young man whose case triggered the investigation at Sahlgrenska University Hospital at the University of Gothenburg, Sweden, that led to a brand new diagnosis.

20 Apr 2010

NextBio announces new Sequence-Centric module for mining high throughput array and sequencing data

NextBio today announced the latest evolution of its innovative life science research platform, adding new capabilities for the integration and mining of high-throughput array and next-generation sequencing data. The new NextBio Sequence-Centric module enables researchers to effectively explore and utilize massive amounts of public and internally generated sequencing data, while allowing organizations to create corporate-wide genomic data platforms to serve the needs of their global research teams.

20 Apr 2010

Striking down breast cancer related gene patent may not impact industry, says New York attorney

The recent decision in a Federal District Court in New York to strike down a patent for the breast cancer related BRCA-1 gene may not have the broad impact on the technology industry it had originally been feared to, says a New York attorney.

20 Apr 2010

RANKL inhibition may prove effective in treatment of human malignancy, suggests study

Amgen today announced results of a preclinical study demonstrating a positive response to administration of RANK-Fc against mammary tumor formation in mouse models. OPG-Fc and RANK-Fc bind to and block the action of RANKL. These molecules have a comparable mechanism of action to denosumab. The study was presented today in a late-breaking abstract at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 in Washington, D.C.

20 Apr 2010

Artificial human skin with dermis made from fibrin-agarose biomaterial

Scientists from the University of Granada, Spain, have generated artificial human skin by tissular engineering basing on agarose-fibrin biomaterial. The artificial skin was grafted onto mice, and optimal development, maturation and functionality results were obtained. This pioneering finding will allow the clinical use of human skin and its use in many laboratory tests on biological tissues -which, additionally, would avoid the use of laboratory animals.

20 Apr 2010

Severe and necrotizing AP characterized by depletion of circulating lymphocytes

Mortality of patients with severe acute pancreatitis (SAP) approaches 30%-40%. An imbalance between the early systemic inflammatory response syndrome (SIRS), and the later compensatory counter-inflammatory response, and development of multiple organ failure (MOF) are considered to be the primary causes of morbidity and mortality in SAP. Excessive leukocyte activation (including neutrophils and monocyte-macrophage lineage) with cytokinemia play a critical role in the pathogenesis of pancreatitis and even more so, of the subsequent inflammatory response.

20 Apr 2010

Magnetically guided nanoparticles for delivering DNA, cells and drugs

Scientists and engineers have used uniform magnetic fields to drive iron-bearing nanoparticles to metal stents in injured blood vessels, where the particles deliver a drug payload that successfully prevents blockages in those vessels. In this animal study, the novel technique achieved better results at a lower dose than conventional non-magnetic stent therapy.

20 Apr 2010

CINJ: Common genetic variation impacts diagnosis of breast cancer in postmenopausal women

Researchers from The Cancer Institute of New Jersey are converging on Washington, D.C., this week for the 101st Annual Meeting of the American Association for Cancer Research (AACR) to share their findings on how a common genetic variation can impact diagnosis of breast cancer in postmenopausal women.

20 Apr 2010

Study underscores potential for VBL Therapeutics VB-111 as broad-spectrum cancer therapy

VBL Therapeutics today announced positive results from preclinical and Phase 1 studies evaluating the company's lead anti-cancer agent, VB-111 - a first-in-class, targeted biological agent shown to work via dual-action, anti-angiogenic and vascular disruptive mechanism of action - in metastatic cancer. Preclinical data evaluating VB-111 in a comprehensive set of in vivo studies employing the Lewis Lung metastasis mouse model showed the compound to be safe and specific, with a 90% reduction in tumor burden of lung metastases after only one injection.

20 Apr 2010

NanoString Technologies launches new miRNA assay kits

NanoString Technologies, Inc., a privately held life sciences company marketing a complete solution for detecting and counting large sets of target molecules in biological samples, today announced a unique new product for miRNA analysis that includes a multiplexed assay for profiling the human miRNA transcriptome in a single tube. The company introduced the new assay kit, which expands the applications for its nCounter® Analysis System, at the American Association for Cancer Research annual meeting.

From NanoString Technologies 20 Apr 2010

LifeSpan BioSciences increases number of catalogued, validated IHC-plus antibodies to over 3,500

LifeSpan BioSciences, Inc., a leading provider of antibodies for thousands of researchers worldwide, has increased the number of validated IHC-plus™ antibodies available in its catalog to more than 3,500. With this increase, LifeSpan is well on its way to building the world's largest catalog of well characterized, IHC-validated reagent antibodies. Overall, LifeSpan has a catalog of more than 82,000 antibodies.

20 Apr 2010

XOMA 052 antibody demonstrates potential for treatment of myeloma patients with elevated IL-6 levels

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced that independent researchers presented results showing that XOMA's antibody to interleukin-1 beta (IL-1 beta), XOMA 052, was highly effective in reducing production of a protein that supports the proliferation of cancerous human myeloma cells in vitro.

20 Apr 2010

PTEN expression clinically useful in assessing risk of prostate cancer recurrence: Study

Myriad Genetics, Inc. today said results from a recent study indicate that expression of the PTEN gene may be clinically useful in assessing a man's risk of prostate cancer recurrence after radical prostatectomy.

20 Apr 2010

Boston Biomedical to present updated Phase I study data of BBI608 cancer drug at 101st AACR

Researchers at Boston Biomedical, Inc., are working to develop a novel first-in-class cancer drug that works by targeting the stem like properties of some cancer cells, and so far, results of an ongoing Phase I clinical trial demonstrate early signs of a strong safety profile and clinical activity.

20 Apr 2010

Medical Science News

NEDD9 protein plays significant role in development of HER2-driven breast cancer: Researchers

Semafore Pharmaceuticals' SF1126 PI3K-mTOR inhibitor demonstrates broad anti-tumor activity in lymphoma

New web-based service for analyzing, visualizing and managing DNA sequencing data

Platelet rich plasma helps speed healing and bone formation following tooth removal

MUC1 expression indicates progression of pediatric inflammatory bowel disease

Affymetrix introduces new service for obtaining allele-specific copy number data from FFPE samples

Genetic defect in protein glycogenin can lead to cardiac arrest

NextBio announces new Sequence-Centric module for mining high throughput array and sequencing data

Striking down breast cancer related gene patent may not impact industry, says New York attorney

RANKL inhibition may prove effective in treatment of human malignancy, suggests study

Artificial human skin with dermis made from fibrin-agarose biomaterial

Severe and necrotizing AP characterized by depletion of circulating lymphocytes

Magnetically guided nanoparticles for delivering DNA, cells and drugs

CINJ: Common genetic variation impacts diagnosis of breast cancer in postmenopausal women

Study underscores potential for VBL Therapeutics VB-111 as broad-spectrum cancer therapy

NanoString Technologies launches new miRNA assay kits

LifeSpan BioSciences increases number of catalogued, validated IHC-plus antibodies to over 3,500

XOMA 052 antibody demonstrates potential for treatment of myeloma patients with elevated IL-6 levels

PTEN expression clinically useful in assessing risk of prostate cancer recurrence: Study

Boston Biomedical to present updated Phase I study data of BBI608 cancer drug at 101st AACR

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News